Mymetics Corporation, a vaccine company, focuses on developing vaccines for infectious diseases primarily in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, chikungunya, herpes simplex virus, and the respiratory syncitial virus (RSV) vaccine. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone011-41-21-653-4535
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.71 million
Profitability
Miscellaneous
Employees9
Next Earnings Date4/4/2019 (Estimated)
OptionableNot Optionable
Mymetics (OTCMKTS:MYMX) Frequently Asked Questions
What is Mymetics' stock symbol?
Mymetics trades on the OTCMKTS under the ticker symbol "MYMX."
When is Mymetics' next earnings date?
Has Mymetics been receiving favorable news coverage?
Headlines about MYMX stock have trended negative recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mymetics earned a coverage optimism score of -2.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Mymetics' key competitors?
Some companies that are related to Mymetics include BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Vical (VICL), CytRx (CYTR), Titan Pharmaceuticals (TTNP), Windtree Therapeutics (WINT), TrovaGene (TROV), Vaxart (VXRT), aTyr Pharma (LIFE), Aevi Genomic Medicine (GNMX), Genetic Technologies (GENE), Neuralstem (CUR), Enzon Pharmaceuticals (ENZN), Mateon Therapeutics (MATN) and Vitro Diagnostics (VODG).
What other stocks do shareholders of Mymetics own?
Who are Mymetics' key executives?
Mymetics' management team includes the folowing people:
- Mr. Ronald Kempers, CEO, Pres & CFO (Age 51)
- Dr. Sylvain Fleury, Chief Scientific Officer (Age 57)
- Mr. Anthony Jessop, Sr. VP (Age 78)
- Dr. Antonius Johannes Stegmann, Head of R&D and Chief Scientific Officer of Mymetics BV
- Mr. Mario Amacker Ph.D., Head of Quality & Manufacturing
How do I buy shares of Mymetics?
Shares of MYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mymetics' stock price today?
One share of MYMX stock can currently be purchased for approximately $0.0390.
How big of a company is Mymetics?
Mymetics has a market capitalization of $11.85 million and generates $1.71 million in revenue each year. Mymetics employs 9 workers across the globe.
What is Mymetics' official website?
How can I contact Mymetics?
Mymetics' mailing address is Route de la Corniche 4, Epalinges V8, 1066. The company can be reached via phone at 011-41-21-653-4535 or via email at [email protected]
MarketBeat Community Rating for Mymetics (OTCMKTS MYMX)
MarketBeat's community ratings are surveys of what our community members think about Mymetics and other stocks. Vote "Outperform" if you believe MYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
